Pharmacyclics Inc. is a clinical-stage biopharmaceutical company focused on developing and commercializing small-molecule drugs for the treatment of immune mediated disease and cancer. Its pharmaceutical drug development candidates are synthetic small-molecules designed to focus key biochemical pathways involved in human diseases. The Company has four product candidates in clinical development and two product candidates in pre-clinical development. This includes a histone deacetylase inhibitor (PCI-24781); an inhibitor of Factor VIIa (PCI-27483); an inhibitor of Bruton's tyrosine kinase (Btk) (PCI-32765); a series of Btk inhibitors in advanced preclinical lead optimization and testing targeting autoimmune and allergic indications, and HDAC8 inhibitors (PCI-34051 and others). Motexafin gadolinium (MGd) completed accrual in two Phase II trials.